These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 33537861)

  • 61. A case of capecitabine-induced coronary microspasm in a patient with rectal cancer.
    Arbea L; Coma-Canella I; Martinez-Monge R; García-Foncillas J
    World J Gastroenterol; 2007 Apr; 13(14):2135-7. PubMed ID: 17465463
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Rare Presentation of Cardiotoxicity Related to 5-Fluorouracil.
    Charkviani M; Murvelashvili N; Barrera F; Sharma A; Eldin RS; Nabil NUN
    Case Rep Oncol Med; 2020; 2020():4151474. PubMed ID: 32774961
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Cardiotoxicity of 5-fluorouracil: report of 6 cases].
    Timour Q; Lombard-Bohas C; Slim R; Barel C; Bui-Xuan B; Tabib A; Bricca G; Malonne H; Vial T; Iordescu D; Descotes J
    Therapie; 2002; 57(3):302-6. PubMed ID: 12422546
    [TBL] [Abstract][Full Text] [Related]  

  • 64. DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.
    Henricks LM; Opdam FL; Beijnen JH; Cats A; Schellens JHM
    Ann Oncol; 2017 Dec; 28(12):2915-2922. PubMed ID: 29045513
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil.
    Frickhofen N; Beck FJ; Jung B; Fuhr HG; Andrasch H; Sigmund M
    Ann Oncol; 2002 May; 13(5):797-801. PubMed ID: 12075751
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Reintroduction of 5-Fluorouracil Post-cardiac Arrest Secondary to Chemotherapy-Induced Cardiotoxicity.
    Wu K; Bhattacharya P
    Cureus; 2023 Jan; 15(1):e34232. PubMed ID: 36852353
    [TBL] [Abstract][Full Text] [Related]  

  • 67. 5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity.
    Jensen SA; Sørensen JB
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):57-64. PubMed ID: 21603868
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Diagnosis and Management of a Patient With 5-Fluorouracil-Induced ST Elevation and Nonsustained Ventricular Tachycardia as a Late Presentation of Cardiotoxicity and Successful 5-Fluorouracil Rechallenge.
    Medepalli LC; Mahmood TS; Liberman H; Medepalli AM; Bagwell TW
    Cureus; 2022 Oct; 14(10):e30489. PubMed ID: 36415417
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
    Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
    Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study.
    Akhtar SS; Salim KP; Bano ZA
    Oncology; 1993; 50(6):441-4. PubMed ID: 8233284
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Cardiotoxicity of 5-fluorouracil].
    Pan L; Yang X; Song H
    Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):86-9. PubMed ID: 8758800
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Coronary Artery Vasospasm Induced by 5-fluorouracil: Proposed Mechanisms, Existing Management Options and Future Directions.
    Chong JH; Ghosh AK
    Interv Cardiol; 2019 May; 14(2):89-94. PubMed ID: 31178935
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Uridine Triacetate for Severe Fluoropyrimidine Cardiotoxicity in a Patient With Thymidylate Synthase Gene Variants.
    Raber I; Frazer MB; Zerillo JA; Asnani A
    JACC CardioOncol; 2020 Jun; 2(2):329-332. PubMed ID: 34396241
    [No Abstract]   [Full Text] [Related]  

  • 74. Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm.
    Shah NR; Shah A; Rather A
    J Oncol Pharm Pract; 2012 Mar; 18(1):132-5. PubMed ID: 21321041
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A case of 5-fluorouracil cardiotoxicity simulating acute myocardial infarction.
    Mizuno Y; Hokamura Y; Kimura T; Kimura Y; Kaikita K; Yasue H
    Jpn Circ J; 1995 May; 59(5):303-7. PubMed ID: 7596036
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clozapine associated cardiotoxicity: Issues, challenges and way forward.
    Kanniah G; Kumar S
    Asian J Psychiatr; 2020 Apr; 50():101950. PubMed ID: 32109805
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Various Manifestations of 5-Fluorouracil Cardiotoxicity: A Multicenter Case Series and Review of Literature.
    Allison JD; Tanavin T; Yang Y; Birnbaum G; Khalid U
    Cardiovasc Toxicol; 2020 Aug; 20(4):437-442. PubMed ID: 31925673
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review.
    Saneeymehri SS; Markey KR; Mahipal A
    J Oncol Pharm Pract; 2016 Jun; 22(3):552-5. PubMed ID: 25852107
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cardiotoxicity and capecitabine: a case report.
    Singer M
    Clin J Oncol Nurs; 2003; 7(1):72-5. PubMed ID: 12629938
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
    Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
    Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.